Get the Stockscreener App
9.56
0.74%
0.07
After Hours:
9.56
Anika Therapeutics Inc stock is traded at $9.56, with a volume of 192.91K.
It is up +0.74% in the last 24 hours and down -5.35% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$9.49
Open:
$9.5
24h Volume:
192.91K
Relative Volume:
1.46
Market Cap:
$137.87M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-1.8856
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-0.42%
1M Performance:
-5.35%
6M Performance:
-15.17%
1Y Performance:
-44.84%
1-Day Range:
$9.48
$9.65
1-Week Range:
$9.4702
$9.75
52-Week Range:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.56 | 136.86M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Responsive Playbooks and the ANIK Inflection - news.stocktradersdaily.com
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP - GlobeNewswire
Is Anika Therapeutics Inc a good long term investmentRetail Trading Trends & Minimize Portfolio Damage with Warnings - earlytimes.in
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 2025CEO Change & Weekly Return Optimization Alerts - Newser
Can Anika Therapeutics Inc. (AKP) stock ride next bull market cycleIPO Watch & Short-Term Swing Trade Alerts - Newser
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%? - Yahoo Finance
Why Anika Therapeutics Inc. (AKP) stock stays on top picksQuarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Is Anika Therapeutics Inc. stock a buy before product launchesJuly 2025 EndofMonth & Verified Technical Signals - Newser
Anika Therapeutics (ANIK) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Anika Therapeutics Inc. stock reacts to global recession fears2025 Earnings Impact & Weekly Market Pulse Updates - Newser
United States Joint Pain Injection Market Surges at 12% CAGR - openPR.com
Understanding the Setup: (ANIK) and Scalable Risk - news.stocktradersdaily.com
Anika Therapeutics Inc.Common Stock (NQ: ANIK - Markets Financial Content
Osteoarthritis Therapeutics Market Key PlayersShare Consolidation Trends & Capital Growth Signals - openPR.com
Anika Therapeutics Reports Mixed Q3 2025 Results - MSN
How Anika Therapeutics Inc. stock responds to policy changes2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Envestnet Asset Management Inc. Boosts Stake in Anika Therapeutics Inc. $ANIK - Defense World
How Anika Therapeutics Inc. (AKP) stock reacts to Fed tighteningMarket Volume Report & Smart Money Movement Alerts - newser.com
Can Anika Therapeutics Inc. (AKP) stock deliver consistent EPS growthJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Will Anika Therapeutics Inc. (AKP) stock hit analyst forecastsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Will Anika Therapeutics Inc. stock benefit from sector rotationWeekly Investment Report & Fast Gain Stock Tips - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy on weakness - newser.com
How strong is Anika Therapeutics Inc. stock balance sheetJuly 2025 Outlook & Daily Volume Surge Signals - newser.com
How Anika Therapeutics Inc. (AKP) stock reacts to fiscal policies2025 Earnings Impact & Technical Entry and Exit Tips - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.2025 Retail Activity & AI Driven Price Forecasts - newser.com
Is Anika Therapeutics Inc. stock attractive after correctionJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flowsEarnings Performance Report & Real-Time Stock Entry Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock a buy before new product rolloutIPO Watch & Daily Profit Maximizing Tips - newser.com
Why Anika Therapeutics Inc. (AKP) stock stays resilient2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Will Anika Therapeutics Inc. stock reach all time highs in 20252025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock resilient in recession scenariosPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):